

Charity Registration No. 1166012

Company Registration No. 9816385 (England and Wales)

BRITISH THORACIC ONCOLOGY GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 MARCH 2022**

BRITISH THORACIC ONCOLOGY GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Mr A M Grange (Chairman) Mr C Kerr (Treasurer) Professor M D Peake Ms S Hiom Professor D Talbot
Senior Executive Officer	Ms D E McKinley
Steering Committee Chair	Professor S Popat
Steering Committee Vice-Chair	Dr T Newsom-Davis
Charity number	1166012
Company number	9816385
Principal address	235 Loughborough Road Mountsorrel Loughborough Leicestershire LE12 7AS
Registered office	West Walk Building 110 Regent Road Leicester LE1 7LT
Independent examiner	P T Barnett FCCA Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT
Bankers	Santander UK plc Bridle Road Bootle Merseyside L30 4GB

BRITISH THORACIC ONCOLOGY GROUP

CONTENTS

	Page
Trustees' report	1 - 29
Independent examiner's report	30
Statement of financial activities	31
Balance sheet	32
Statement of cash flows	33
Notes to the financial statements	34 - 43

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2022

The trustees, who are the directors of the charitable company, present their report and financial statements for the year ended 31 March 2022.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: Statement of Recommended Practice for Charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The legal and administrative information forms part of this report.

OBJECTIVES AND ACTIVITIES

The charitable objects are:

- (1) The promotion and advancement of health or the saving of lives by way of improving the care of patients with thoracic malignancies through multi-disciplinary education and clinical and scientific research for the benefit of the public;
- (2) To advance public education and research into lung cancer and mesothelioma, in particular but not exclusively by facilitation of exchange of information on thoracic oncology including disseminating results of research and other news related to lung cancer and mesothelioma;
- (3) Such other charitable purposes beneficial to the community consistent with the objects as above as the trustees shall in their absolute discretion determine.

Vision and Mission

The vision of British Thoracic Oncology Group ("BTOG") is to contribute to achieving survival rates equal to the best in the world.

The mission of BTOG is to support and educate thoracic oncology health care professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care.

BTOG's Values

- We are committed to achieving our vision and mission.
- We are proud to be an important part of the thoracic oncology professional community.
- We work collaboratively with other groups who in their own ways are also striving to improve outcomes for this group of patients or reduce the prevalence of lung cancer e.g. relating to smoking cessation.
- We engage with our stakeholders to ensure what we do is relevant and effective.
- We maintain professional independence from commercial organisations.
- We hold patients at the centre of everything we do.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

OBJECTIVES AND ACTIVITIES (CONTINUED)

Activities for achieving objectives for the public benefit

The Board of Trustees ("trustees") has had regard to the Charity Commission's guidance on public benefit. The main activities undertaken to further the charitable purposes for the public benefit are set out below:

Education:

- Provides an annual CPD education programme of value to the whole multi-disciplinary team (MDT).
- Provides access to events for advocates who sit on thoracic oncology clinical studies or trial management groups, advisory boards/groups or other related groups.
- Ensures registration fees are accessible to members of the MDT.
- Provides an education bursary for the annual conference and other events where possible.
- Provides a membership for thoracic oncology health care professionals including access to useful resources (regular BTOG E-News; a website member only on-line resource including films and presentations from BTOG educational events and access to an online lung cancer journal; opportunity to participate in relevant research studies/questionnaires and provide an up-to-date calendar of thoracic oncology events).

Research:

- Provides networking opportunities at educational events and foster a professional community through its membership for the research community to develop clinical trials and other research.
- Provides workshops or stand-alone events for the sole purpose of research development.
- Circulates research surveys and questionnaires that support relevant research.
- Is a member of relevant research groups (e.g. European Thoracic Oncology Platform, International Association for the Study of Lung Cancer).

Representation:

- Reviews NICE appraisals for new drug therapies/technologies.
- Reviews appropriate guidelines/policy documents.
- Develops BTOG-own guidelines/position documents.
- Participates in other groups, sub-groups, committees and boards.
- Represents patients in any capacity it deems appropriate with the overall aim to improve outcomes or reduce the prevalence of lung cancer e.g. relating to smoking cessation.

Criteria to measure success in the reporting period;

We measure our success in achieving our objectives in several of ways:

- By providing an annual CPD education programme of value to the whole multi-disciplinary team and receiving good feedback from attendees and consistent or increased attendance to the events.
- By keeping in touch with the professional community to encourage networking and collaboration virtually.
- By listening to our stakeholders to ensure what we do is relevant and effective through feedback and surveys.
- By working collaboratively with other groups to improve patient outcomes.
- By ensuring that BTOG represents patients in relevant guideline and drug development.

Longer term aims and objectives

In 2020, the BTOG's trustees and Steering Committee worked together to produce the Strategic Plan 2020-2025 taking account of stakeholder needs. Although COVID-19 has impacted the timeline for some of our strategic activities, BTOG is committed to adapting and fulfilling its longer term aims and objectives. Therefore, the Strategic Plan remains a relevant working document.



OBJECTIVES AND ACTIVITIES (CONTINUED)

STRATEGIC PLAN 2020 – 2025

MISSION

To support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research.

The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care.

STRATEGIC ACTIVITIES

- Make www.btog.org the one-stop resource shop for thoracic oncology healthcare professionals
- Identify and communicate with lung and mesothelioma MDTs.
- Engage with Juniors through trainee representation on the steering committee
- Establish a BTOG Regional Champion Scheme to engage with existing members and attract new ones

VISION

To contribute to achieving survival rates equal to the best in the world.

OUR VALUES

We are committed to achieving our mission and vision.

We are proud to be an important part of the thoracic oncology professional community.

We work collaboratively with other groups who in their own ways are also striving to improve outcomes for this group of patients.

We engage with our stakeholders to ensure what we do is relevant and effective.

We maintain professional independence from commercial organisations.

We hold patients at the centre of everything we do.

EDUCATION

- Conference (Flagship Event)
- Essential Updates
- Workshops (ad hoc)
- Annual updates from thoracic oncology international conferences
- Postgraduate Course (Biennial)
- Produce standard slide sets for Changes in Practice / What's New series – included in regional updates
- Produce Breaking News/Alerts/Press Releases for Changes in Practice

RESEARCH

- Facilitate a Think Tank Workshop to identify gaps for development of research with UK, European and other research organisations
- Establish BTOG research specialist subgroups to complement other external subgroups
- Ensure subgroups report regularly on the delivery of specific objectives

REPRESENTATION

- Make reactive contributions: NICE appraisals; Specialist Statement of Practice; Endorsements
- Make proactive contributions: Guidelines; Position and Consensus Statements; Comment on Public Health England / Department of Health Policy
- Campaign with relevant organisations for equitable access to optimal care
- Partner with specialist societies / groups / organisations (e.g. Surgeons, Nurses, Pathologists, Radiologists)
- Engage with advocates by ensuring advocate representation on the BTOG steering committee and making advocate places available at BTOG educational events
- Represent all the UK including the devolved nations

STRATEGIC OUTCOMES

- To reach all lung/mesothelioma MDTs in the UK to ensure all thoracic oncology healthcare professionals have access to relevant education and resources
- To be a leader in thoracic oncology research to focus and support the research agenda
- To represent thoracic oncology patients by making contributions and collaborating with others

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE

Review of Activities - Education

In common with all organisations, the COVID-19 pandemic has had a significant impact on the in-person events and networking of BTOG. During the period April 2021 to March 2022 due to continued COVID-19 restrictions and the risk involved for in-person events our educational activities remained on-line.

During the 2021/22 year, BTOG has worked hard to provide a relevant Continuing Professional Development (CPD) education programme for the thoracic oncology multi-disciplinary team. Advocates who sit on thoracic oncology clinical studies or trial management groups, advisory boards/groups or other related groups are welcome to register for BTOG education (except for the BTOG Journal Club which is for trainees).

Annual Conference

During this period BTOG held two virtual annual conferences, one in April 2021 (delayed from January 2021) and one in January 2022. For BTOG 2021, in recognition of challenging times, BTOG registration fees were waived for all health care professionals.

BRITISH THORACIC ONCOLOGY GROUP


TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)


Review of Activities - Education (continued)





ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Some Feedback from our Annual Conference in 2021

- Brilliantly organised! A credit to all involved. It was very good and informative.
- Well-structured and sessions ran very well.
- Excellent presentations. Very well organised meeting.
- Excellent programme and well organised. Interactive - Q and A sessions livened up the “virtual” world. Hoping next year returns to normal face to face meetings but this is a good 2nd best.
- Greatly appreciated the conference being available online. I found it extremely helpful.
- Great conference. Whilst missed the face-to-face interaction of conference it was helpful being able to view the difference streams- sometimes it can be hard to decide which stream to attend.

Some Feedback from our Annual Conference in 2022

- BTOG is incredibly useful for clinicians who work in smaller centres, to maintain up to date NHS relevant knowledge, to learn from other centres who share expertise in systems and services that have adapted well to the NHS pressures/pandemic pressures. It provides us with up-to-date information on the latest availability of treatments that are not yet fully NICE approved/funded etc.... I think it should be mandatory to attend as a lung oncologist!!
- Good balance of content across key specialties, but mostly aimed at general audience which was good.
- I have been to BTOG many times and usually always come back with lots of information to pass onto my colleagues.
- As always, an excellent conference with the live platform functioning well.
- I found the virtual platform very impressive - it was easy to navigate, and the hotel lobby design was a nice touch.
- The variety of topics and involvement of all types of Specialists in Oncology Care, including those in allied services such as dietician and physio and psychology was great to see at a major Conference.

Webinars



BTOG continued with its regular 1-hour webinars that were developed last year taking account of the latest data released and included a panel of relevant experts in thoracic oncology. Registration at all BTOG webinars is free of charge for health care professionals.

We held nine 1-hour webinars and two full-day webinars during this period and all webinars were accredited by the Federation of the Royal Colleges of Physicians of the UK for category 1 (external) CPD credits. CPD credits were available both live and up to 4 weeks post-event for on-demand and the stats provided below reflect this timeframe. Attendees were encouraged to give feedback on the content and organisation and any feedback was recorded and analysed to ensure continuous improvement. All BTOG webinars are also available to view 'On Demand' in the BTOG Member Resources area.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Live and on-demand

The 11 BTOG webinars during this period resulted in a total audience of 1,029 live and on demand (up to 4 weeks).

813 attendees to the following 9 webinars:

#BTOGWebinars #BTOGMesoWebinar
BTOG Webinar: Mesothelioma Essential Update
Monday 17th May 2021 • 17:30 – 18:30 GMT

#BTOGWebinars #BTOGWebinar #BTOGASCO21
BTOG Webinar: 'ASCO 2021 in an Hour'
Thursday 10th June 2021 • 17:30 – 18:30 BST

Dr. David Gilligan, BTOG Steering Committee Vice Chair and Consultant Oncologist
Dr. David Gilligan, Consultant Medical Oncologist
Dr. David Gilligan, Consultant Medical Oncologist
Dr. David Gilligan, Consultant Medical Oncologist

#BTOGWebinars #BTOGMasterclass #BTOGperiOp
BTOG Masterclass: Peri-Operative Therapies
Thursday 29th July 2021 • 17:30 – 18:30 BST

Professor Dennis Saker, Professor of Experimental Cancer Medicine and Consultant in Medical Oncology, Royal College of Surgeons in Ireland
Dr. David Gilligan, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust
Professor Barbara Ahmed, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust

#BTOGWebinars #WCLCandESMOinAnHour
WCLC & ESMO 2021 in an Hour
Monday 21st September 2021 • 17:30 – 18:30 BST

Tom Newman-Davis, BTOG Steering Committee Vice Chair
Dr. David Gilligan, Consultant Oncologist
Samreen Ahmed, Consultant in Medical Oncology
Riyaz Shah, Consultant Medical Oncologist

#BTOGwebinars #BTOGwebinarRTtechniques
Advanced RT techniques: Tips and tricks for challenging cases
Thursday 7th October 2021 • 7:30 – 18:30 BST

Professor Matthew Horton, Weston Park Cancer Centre and Chair of the National Cancer Research Institute Lung Cancer Study Group
Dr. David Gilligan, Consultant Medical Oncologist at the Royal Marsden Hospital
Corinne Fothergill, Honorary Consultant Oncologist and a Member of the National Cancer Research Institute Lung Cancer Study Group
Liam Walsh, Consultant Clinical Oncologist, Neuro-oncology Unit at the Royal Marsden

#BTOGEssentialUpdate #BTOGsupportingpatients
BTOG Essential Update: Supporting Patients with Thoracic Malignancies
Wednesday 10th November 2021 • 7:30 – 18:30 GMT

Tom Newman-Davis, BTOG Steering Committee Vice Chair
Nehal English, Clinical Nurse Specialist, Honorary Medical Oncologist, Consultant, West of Scotland Cancer Centre
Professor Maria Salter, MRC Clinical Trials Unit at UCL, Honorary Consultant in Palliative Medicine and Honorary Consultant in Palliative Care, University of Edinburgh
Barry Lavelle, Senior Clinical Lecturer in Palliative Medicine and Honorary Consultant in Palliative Care, University of Edinburgh

#BTOGmasterclass #BTOGimmunotherapy
BTOG Masterclass: Immunotherapy Tips and Tricks
Thursday 9th December 2021 • 17:30 – 18:30 BST

Professor Saeed Hossain, Consultant Medical Oncologist, Honorary Consultant in Medical Oncology, University of Leicester
Dr. David Gilligan, Consultant Medical Oncologist, University of Leicester
Dr. David Gilligan, Consultant Medical Oncologist, University of Leicester
Dr. David Gilligan, Consultant Medical Oncologist, University of Leicester

#BTOGwebinars #BTOGImagingWebinar
How do we harness functional imaging information in Radiotherapy?
Thursday 24th February 2022 • 7:30 – 18:30 BST

Dr. David Gilligan, BTOG Steering Committee Vice Chair
Dr. David Gilligan, Consultant Medical Oncologist, University of Leicester
Dr. David Gilligan, Consultant Medical Oncologist, University of Leicester
Dr. David Gilligan, Consultant Medical Oncologist, University of Leicester

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022




216 attendees to the following 2 webinars:



Speciality/Category	%
Nursing	9.4%
Medical Oncology	19.7%
Clinical Oncology	25.4%
Oncology	3.7%
Respiratory	21.7%
Surgery	0.4%
Palliative Care	0.4%
Radiology	2.0%
Science/research/clinical trials	2.5%
Pharmacy	1.6%
Academic	0.8%
Student	0.0%
Pathology	1.6%
Allied HCP	1.6%
Other HCP	1.6%
Industry	5.3%
Patient advocate	1.2%
Charity/non-profit	0.4%
Other non-HCP	0.4%

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



BTOG held the Second BTOG Lung Cancer Screening Essential Update on Friday 11th June 2021 – this full day online event brought together national experts to discuss existing Lung Cancer Screening Projects in the UK and future plans and potential impact on their clinical practice. Parallel tracks provided detailed information and increased understanding on the screening roll out and knowledge relevant to professionals involved in thoracic oncology. A combination of short presentations from currently active screening/lung health check programmes and questions and debate gave attendees in depth knowledge to be related to their practice.



BTOG held a BTOG Masterclass: Leading your lung cancer pathway on Friday 8th October 2021 – this full day online event brought together national experts to discuss how to develop a lung cancer service and how to lead a lung cancer service, to learn about new developments related to running a lung cancer service and understanding unwarranted variation, to learn about managing the governance arrangements in a lung cancer service and horizon scanning for new challenges and opportunities.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Feedback for Webinars

- Really enjoyed the meeting.
- Perfectly organised webinar on actual topics.
- A very informative session.
- Brilliant session- best yet! (Though may be biased as a clinical oncologist). Found session on brain mets particularly interesting.
- Excellent session, very helpful, nothing to improve. Thanks.
- Excellent as always.
- Very good overview of ESMO and WCLC 2021.
- Super informative session! Really enjoyed this update and great speakers - no improvements needed!
- Useful update.
- Well done; thank you.
- Just to say that I really enjoy the 'head-to-head' format on some of them. It helps air thorny issues.
- V good clear answers to questions, nice non-combative styles, congenial tone set by Chair.
- Another well organised and very useful BTOG webinar!
- Excellent up to date summary of current situation re meso treatment.



Impressions: The number of impressions on a tweet sent in the selected date range. An impression is the number of times a tweet appears to users in either their timeline or search results.

Engagements: The total number of times a user interacted with the tweets you sent during the selected date range.

A total of 837,137 impressions on event hashtags:

#BTOGsupportingpatients	124,808 impressions
#BTOGimmunotherapy	101,685 impressions
#BTOGPeriOp	100,086 impressions
#WCLCandESMOinAnHour	91,374 impressions
#BTOGscreeningupdate	85,895 impressions
#BTOGmasterclass	82,389 impressions
#BTOGwebinarRTtechniques	80,218 impressions
#BTOGLCpathway	73,806 impressions
#BTOGimagingwebinar	35,575 impressions
#BTOGASCO21 / #BTOGASCO2021	33,733 impressions
#BTOGmesoWebinar	24,556 impressions
#BTOGlungcancerdiagnostics	3,012 impressions

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)




Podcasts of all BTOG webinars are available to listen to or download. BTOG introduced a series of podcasts called “*BTOG does ...*” where we discussed a variety of thoracic oncology topics with a different expert each time. BTOG podcasts can be subscribed to through the Apple App Store and the Google Play Store or be listened to on Spotify by searching BTOG (CPD points are not available for the podcasts).

During this period a total of 2,614 podcast downloads.

	Downloads					
	Jan-Mar22	Oct-Dec21	Jul-Sep21	Apr-Jun21	Jan-Mar21	Oct-Dec20
TOTALS	1,500	806	348	478	373	233
CHANGE	↑86%	↑132%	↓27%	↑28%	↑60%	

Dedicated podcast series started November 2021



BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Total podcasts downloads:

BTOG does ...	Expert	Interviewer	
EGFR Mutated lung cancer	Samreen Ahmed	Tom Newsom-Davis	209
Diagnosis and Staging	Neal Navani	Tom Newsom-Davis	191
CURE Project & Tobacco Addiction	Matt Evison	Helen McDill	186
Lung cancer screening	Emma O' Dowd	Helen McDill	181
Lung Histopathology	Angeles Montero-Fernandez	Tom Newsom-Davis	151
BTOG 20th Anniversary	Sanjay Popat	Tom Newsom-Davis	114
Oligometastatic disease and SABR	David Palma	Stephen Harrow	195
Management of Pleural Disease	Nick Maskell	Helen McDill	199
Management of Cancer Cachexia	Barry Laird	Stephen Harrow	187
			1613
WEBINARS – available data at time of reporting			
BTOG Webinar: Mesothelioma Essential Update			225
BTOG Masterclass: Peri-Operative Therapies			145
WCLC 2021 & ESMO 2021 in an Hour			126
BTOG Webinar: Advanced Radiotherapy Techniques			117
BTOG Essential Update on Supporting Patients with Thoracic Malignancies			127
BTOG Masterclass: Immunotherapy Tips & Tricks			261
			1001

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



BTOG introduced a regular virtual journal club on the latest trials in thoracic oncology facilitated by experts and discussing all things from trial design to results interpretation and their implications for clinical practice. The target audience for the Journal Club is medical trainees of all grades including medical students and allied health professionals and attendee numbers are restricted to allow for and encourage interaction and discussion.

Moderator: Professor Allan Hackshaw, Professor of Epidemiology & Medical Statistics, Deputy Director, Cancer Research UK & UCL Cancer Trials Centre

BTOG Trainee Representatives: Adam Januszewski, Higher Specialty Trainee in Medical Oncology and Honorary Clinical Fellow, Imperial College London and Helen McDill, Respiratory Registrar, Gloucestershire Royal Hospital

Thursday 24th June 2021

Paper: CheckMate 743 investigating the use of first line ipilimumab and nivolumab in mesothelioma

Expert: Dr Riyaz Shah, Consultant Medical Oncologist, Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust

Wednesday 21st July 2021

Paper: Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial Slotman et al

Expert: Dr Clive Peedell, Consultant Clinical Oncologist, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust

Wednesday 29th September 2021

Paper: Nelson Trial 'Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomised Trial' Koning et al

Expert: Dr Anna Sharman, Consultant Thoracic Radiologist, Wythenshawe Hospital

Wednesday 8th December 2021

Paper: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial – Albain et al (Intergroup Trial 0139)

Expert: Dr Matthew Evison, Consultant Physician in Respiratory Medicine (Thoracic Oncology), North West Lung Centre and University of Manchester

Friday 28th January 2022

Paper: Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study – Gomez et al

Expert: Dr Fiona McDonald, Consultant Thoracic Clinical Oncologist, The Royal Marsden NHSFT

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG Trainees Network Launched in January 2022

One of BTOG's key aims is to bring the thoracic oncology community closer together and foster collaboration and education. In BTOG's trainee survey in 2021 we heard that trainees wanted to be connected with other like-minded trainees and therefore we launched the '**BTOG Trainees Network**'. The Slack platform (QR code to join) is designed to bring trainees together from across disciplines and the UK to foster collaborations, open opportunities and foster a community of like-minded trainees. The platform is also used to highlight educational events and opportunities.



Online resources at www.btog.org

BTOG Trainee Representatives have been working on a major upgrade to our online resource library, where members can access all the videos and presentations from our education events. A new search function will enable all members to find relevant resources by various categories, by event or by the type of resource. The goal is to create a kind of 'one-stop-shop' and include many other resources beyond those from our events. The new library will go live during the 2022/23 period.

BTOG Membership

During this period BTOG continued to provide relevant and up-to-date member services.

- Free CPD education (e.g. BTOG webinars and essential updates)
- CPD education (annual conference)
- BTOG Resources member area including BTOG presentation/video library, trainee resources and podcasts
- Full digital edition of Lung Cancer Journal
- Bursaries/scholarships for BTOG meeting registration or travel (subject to application process)
- Weekly E-News including relevant information about education, research, research surveys
- BTOG networking and professional community



- 56 E-News were sent during this period
- 38% average open rate (industry average is 20% for similar emails)
- 5.69% click rate (industry average is 2-4% for similar emails)

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Membership (continued)

March 2022

- 2,023 members (1785 HCP, 238 Network)
- Renewals planned for Autumn 2022
- Only 8 have never logged in
- 1,602 have logged in once
- 176 twice
- 101 three times

March 2021

- 1745 members (1528 HCP, 217 Network)
- 2021 member renewals postponed to 2022
- Only 14 have never logged in
- 1344 have logged in once
- 176 have logged in twice
- 109 have logged in three times

March 2020

- 754 members (668 HCP, 86 Network)
- 2020 member renewals postponed to March 2021

March 2019

- 1059 members (925 HCP, 134 Network)
- March to July 2019 renewals

To ensure compliance to General Data Protection Regulation (GDPR), BTOG contacts its members regularly to renew and opt-in to receive information from BTOG. The next renewal is due Autumn 2022.

Health Care Professionals Members by Speciality

	Mar22	2021	2020	2019
Respiratory	26%	26%	26%	27%
Nursing	22%	22%	22%	27%
Medical Oncology	14%	14%	15%	12%
Clinical Oncology	14%	14%	14%	14%
Oncology	5%	5%	6%	3%
Science/research/clinical trials	4%	4%	4%	3%
Surgery	4%	4%	3%	4%
Radiology	3%	3%	3%	3%
Pathology	2%	2%	2%	3%
Allied HCP	2%	2%	2%	2%
Pharmacy	2%	2%	1%	1%
Palliative Care	1%	1%	1%	1%
Academic	0.5%	0.5%	1%	0.5%
Student	0.8%	0.8%	0%	0%

(Percentages are rounded up)

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Membership (continued)

Health Care Professionals Members' Geography

	2022	2021	2020	2019
Yorkshire and the Humber	187	182	80	86
North West	178	179	79	107
East Midlands	222	213	58	102
North West London	118	116	50	24
South London	102	100	47	48
South West	126	123	42	73
West Midlands	104	105	41	67
Scotland	101	93	39	NA
East of England	101	96	36	57
Kent, Surrey and Sussex	119	114	34	37
North Central and East London	100	92	33	33
Thames Valley	56	54	25	24
Wales	37	36	21	NA
Northern Ireland	18	18	NA	NA
Republic of Ireland	36	35	NA	NA

Based on the sample of 1706 members with the HEE field completed

Network Members by Area of Interest

	2022	2021	2020	2019
Industry	64%	66%	57.1%	62.2%
Patient advocate	12%	10%	17.6%	8.3%
Charity/non-profit	6%	6%	5.5%	6.8%
Other non-HCP	18%	18%	19.8%	19.7%

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Twitter, journal and website



3,047 followers - 18% increase

	New Followers			
	2021-2022	2020-2021	2019-2020	2018-2019
New	467	479	510	602
Increase	18%	21%	29%	29%

	Mentions ↑ 24%			
	2021-2022	2020-2021	2019-2020	2018-2019
TOTALS	1118	902	926	706

	Impressions ↑ 59%			
	2021-2022	2020-2021	2019-2020	2018-2019
TOTALS	437,459	274,800	283,600	184,400

Lung Cancer Journal

@LungCaJournal

International peer-reviewed journal on clinical, translational & basic science of lung & chest malignancies [#LCSM](#).
Affiliated with [@BTOGORG](#) [@ETOP_eu](#) and ILCCO

In February 2021, BTOG joined forces with European Thoracic Oncology Platform (ETOP) and International Lung Cancer Consortium (ILCCO) to highlight via twitter significant articles of interest published in the *Lung Cancer Journal*.

Website – www.btog.org

	Users	Pageviews	Avg. session duration	Pages per session
18-19	13,818	86,157	02:14	3.29
19-20	19,679	116,303	01:55	3.56
20-21	18,181	82,029	01:35	3.15
21-22	20,648	155,999	01:50	4.56

70% of traffic is from the UK, 11% from the US, 3% China, 3% Ireland then India, Netherlands, Finland, Germany and France

Devices - 72% is desktop, 26% mobile and 1% tablet

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Twitter, journal and website

Top Referrers


NOTE: Slightly more direct traffic vs search than in 20-21, indicates more people are bookmarking or typing in the web address directly than finding the website through a search.

Top referrers are Eventscloud / btogconference.org, Baidu, Veeva, bsti.org.uk

Google / organic Top search terms: BTOG 2021 and BTOG	34%
(direct) / (none)	46%
Referral	8%
Social (96% Twitter)	5%
Other	7%

Top Pages


1. Home
2. 2022 Annual Conference
3. 2021 Annual Conference
4. Events
5. Webinar listing page
6. Join
7. Podcasts
8. Meet the team
9. Screening Essential Update
10. News



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Research

The poster abstracts from the two BTOG virtual annual conferences were published in a supplement to *Lung Cancer*.



[https://www.lungcancerjournal.info/issue/S0169-5002\(21\)X0006-2](https://www.lungcancerjournal.info/issue/S0169-5002(21)X0006-2)



[https://www.lungcancerjournal.info/issue/S0169-5002\(22\)X0003-2](https://www.lungcancerjournal.info/issue/S0169-5002(22)X0003-2)

A BTOG Special Interest Group (SIG) is a sub-group of the BTOG steering committee with a shared interest in advancing a specific area of thoracic oncology. Members co-operate to affect change or improvement within that speciality. They may communicate, meet, and organise further training or education and resources for the purpose of advancement. They can use the BTOG logo in relation to the SIG. The aim of the BTOG SIGs is to promote the highest standards of knowledge and facilitate research and representation in that specific area of thoracic oncology.

The BTOG Thymic Malignancies SIG, chaired by Dr David Gilligan, met for the first time in January 2020 and following disruption due to the pandemic, reconvened in January 2022. Tumours of the thymus gland constitute a rare but significant part of thoracic oncology. Management of these tumours can be complex and is often poorly understood. The BTOG Thymic Malignancies SIG is a multi-disciplinary group of interested health care professionals, including the patient advocacy group ThymicUK. The aims of this group are to promote understanding, improve knowledge of thymic tumours and to work co-operatively to improve the management pathways for thymic tumours.

During this period, BTOG has also set up a BTOG Large Cell Neuroendocrine Carcinoma (LCNEC) SIG, chaired by Dr Colin Lindsay. The BTOG LCNEC SIG will be meeting in June 2022 for the first time.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022




ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists published September 2021

Lindsay, C.R., Shaw, E.C., Moore, D.A. *et al.* Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. *Br J Cancer* 125, 1210–1216 (2021). <https://doi.org/10.1038/s41416-021-01407-9>

In September 2021, BTOG submitted a supporting Letter to the NIHR an application relating to Prehabilitation for Lung Cancer Surgery.




The NLCA board is constituted by the Society for Cardiothoracic Surgery (SCTS), the Roy Castle Lung Cancer Foundation (representing lung cancer patients), Wales Cancer Network Lung Cancer Group, Lung Cancer Nursing UK (formerly the National Lung Cancer Forum for Nurses) and the **British Thoracic Oncology Group**.

<https://nlca.rcp.ac.uk/content/misc/NLCA%20annual%20report%202022.pdf>


The NLCA board is constituted by the Society for Cardiothoracic Surgery (SCTS), the Roy Castle Lung Cancer Foundation (representing lung cancer patients), Wales Cancer Network Lung Cancer Group, Lung Cancer Nursing UK (formerly the National Lung Cancer Forum for Nurses) and the **British Thoracic Oncology Group**.

[https://nlca.rcp.ac.uk/content/misc/LCCOP%202021\(2018\).pdf](https://nlca.rcp.ac.uk/content/misc/LCCOP%202021(2018).pdf)



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)



BTOG Endorsed the Final Report during this period which was released in April 2022

Endorsements



RCR Radical Thoracic Re-irradiation Guidance – BTOG Endorsed

BTOG endorsed this draft guidance during this period. As the time of this report the guidance is not yet published and it will form part of a wider guidance document in development.

Surveys

BTOG circulated a Pembrolizumab Survey led by Professor Innominato and Dr Ghosal, a team of clinical oncologists, based at the North Wales Cancer Treatment Centre. The survey aims to establish the practice and opinions of oncologists around the country regarding patients with metastatic NSCLC (with no actionable driver mutations), who had to stop 1st line palliative Pembrolizumab after completing two years of treatment in accordance with NICE guidance. The survey objectives are to assist to steer the practice guidance in the future.

BTOG circulated a Survey for Thoracic Clinical Oncologists from National Oncology Trainee Collaborative for Health care Research (NOTCH) regarding the current radiotherapy practice for Thymic Epithelial Tumours (TET). The aim is for at least one response from each radiotherapy centre in the UK to help NOTCH to provide a comprehensive review of UK practice.

TRUSTEES' REPORT (CONTINUED)


FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

Consultations and Inquiries

In August 2021, BTOG contributed to The All Party Parliamentary Group for Respiratory Health inquiry into lung cancer. The inquiry invited expert opinion to inform the group's thinking and to recommend policy solutions for the NHS for implementation to help support the government's policy initiatives on lung cancer.



BTOG submitted evidence to this inquiry. The report was released in November 2021.

<https://www.appg-respiratory.co.uk/>

In January 2022, BTOG contributed to The Health and Social Care Committee's Expert Panel evaluation of the progress the Government has made against its commitments in cancer services in England.

Review of Activities – Representation

BTOG continues to work collaboratively with many organisations, societies, and groups and to build close and enduring relationships and to have mutual memberships to ensure representation. Steering Committee members undertake this work on behalf of BTOG and these include the following examples:

- British Thoracic Society
- Cancer Chemotherapy Interest Group
- European Association for Cardio-Thoracic Surgery (EACTS)
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Thoracic Oncology Platform (ETOP)
- International Association for the Study of Lung Cancer (IASLC)
- Mesothelioma UK
- National Cancer Research Institute (NCRI)
- National Lung Cancer Audit
- Lung Cancer Nursing UK
- Public Health England Implementation Board for Tobacco
- Roy Castle Lung Cancer Foundation
- Royal College of Physicians Tobacco Advisory Board
- Society for Cardiothoracic Surgery (SCTS)
- Taskforce for Lung Health
- UK Mesothelioma Alliance
- UK Lung Cancer Coalition

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation (continued)



NICE Representation

NICE appraisals review and make recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.

During this period Steering Committee members have represented BTOG on **51** NICE appraisals (scoping and full) to review the use of new and existing medicines and treatments within the NHS to ensure clinical and cost effectiveness. **8** NICE appraisals were represented by non-steering committee members – co-opted to represent BTOG.

Participation in the NICE appraisal process involves a significant time commitment by representatives and includes attending appraisal meetings, reviewing lengthy and detailed documents and making comment and recommendations to improve access to treatment for patients.

Samreen Ahmed	11 (1 joint)	Sanjay Agrawal	3	Riyaz Shah	3
Sanjay Popat	9	Clive Peedel	1	David Gilligan	1
Tom Newsom-Davis	6	James Spicer	2	Shobit Baijal	4
Matt Callister	1				
Co-opted (non-SC)					
Alastair Greystoke	2	Mary O'Brien	1	Robin Young	1
Matthew Hatton	1	Yvonne Summers (joint)	1	Matthew Krebs	1
Mark Forster	1 (joint)				

During this period 3 NICE appraisals resulted in recommendations:

- Pembrolizumab with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if:
 - their tumours express PD-L1 with a tumour proportion score of 0% to 49%;
 - their tumours express PD-L1 with a tumour proportion score of 50% or more and they need urgent clinical intervention;
 - it is stopped at 2 years of uninterrupted treatment or earlier if their disease progresses. Recommended February 2022 (ID1683)
- Lung cancer (non-small-cell, advanced, MET gene) - tepotinib [ID3761]. Recommended March 2022 (ID3761)
- Sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults. Recommended March 2022 (ID3780)

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Campaigns



BTOG supports lung cancer campaign

BTOG is proud to have worked in collaboration with Ruth Strauss Foundation, ALK Positive UK and EGFR+UK to develop its [See Through The Symptoms](https://www.lungcancerseethroughthesymptoms.uk/) campaign which raises awareness of lung cancer and the importance of early investigation and referral.

Page 100's photo: Unfortunately, 90% of lung cancer cases diagnosed at stage 3B or 4. Symptoms can include a persistent cough, breathlessness, wheezing, chest pain, blood in sputum, hoarseness or swelling in the face or neck. If you are persistent or unexplained symptoms, please consider a CT scan referred on the Lung Cancer Referral. For more information: <https://www.see-through-the-symptoms.uk>   

Lung Cancer Early Diagnosis Campaign – Launched in May 2021

<https://www.lungcancerseethroughthesymptoms.uk/>



Cancer screening

How can cancer screening programmes be improved throughout the EU?

In August 2021, BTOG wrote to the Federation of European Academies of Medicine (FEAM) regarding the development of a report on cancer screening for the Scientific Advice Mechanism (SAM). BTOG wholeheartedly endorsed the adoption of low-dose computed tomography (LDCT) screening for individuals at high risk of lung cancer.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

FINANCIAL REVIEW

Going Concern

After making appropriate enquiries, the trustees have a reasonable expectation that BTOG has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.


Finance Overview

Last year, the impact of the COVID-19 pandemic was significant, forcing us to cancel our flagship Annual Conference scheduled for January 2021 and replace it with a virtual conference in April 2021. This led to a dramatic downturn in income for the prior year. This year, with the Annual Virtual Conference being in April 2021 and the Annual Conference for this financial year being in January 2022 there has been a large increase in income for sponsorship and registration fees. Total income for the year rose from £19,500 in 2021 to £526,534 in 2022.

The investment in online learning and webinars brought in as our face-to-face educational programme was set aside due to COVID-19 restrictions, has been hugely successful and has been continued.

Total expenditure for the year ended 31 March 2022 amounted to £286,940 (2021 - £143,766). Expenditure has increased this year after the large fall in the prior year due to revised operating conditions during the pandemic. The expenditure was split between charitable activities costs in the sum of £254,155, costs of raising funds in the sum of £32,475 and other expenditure in the sum of £310.

Net income (expenditure) for the year ended 31 March 2022 amounted to £239,594 compared to £(124,266) in the previous year.



Risk Management

A risk policy and a detailed risk register have been produced. The risk register covers governance, external, financial, operational and regulatory risk and a review of the risk register is a standing item at every trustee meeting. The trustees are satisfied that systems and procedures are in place to mitigate exposure to the major risks. A major risk to BTOG is the reliance on registration fees and external sponsorship income to provide enough funding for BTOG to deliver its aims and objectives. This is particularly relevant given the ongoing COVID-19 pandemic. Mitigating actions include strategic planning, operating a reserves policy and ongoing engagement with our key sponsors.

Reserves Policy

BTOG is committed to demonstrate good stewardship and active financial management and to identifying through risk assessment and budgeting any uncertainty in future income streams. A major risk to BTOG is the reliance on registration fees and external sponsorship to provide enough funding for BTOG to deliver its aims and objectives. Therefore, the trustees have agreed that at any one time the charity can hold a maximum of 2 years' normal operating expenditure in reserve (at the time of writing the charity has not yet reached this level of reserve). Normal operating expenditure is identified in annual budgets which are approved by the trustees. This reserve level will ensure that the current service provided by BTOG is secure in times when income to the charity may be reduced.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

FINANCIAL REVIEW (CONTINUED)

Reserves Policy (continued)

Total reserves as at 31 March 2022 amounted to £739,715 of which £nil are restricted. As at 31 March 2022 free reserves (total unrestricted reserves less unrestricted tangible fixed assets) amounted to £739,251 which is significantly below the trustees' long term target level of reserves. At current levels of normal activity, the maximum level of reserves would be in the range of £1m to £1.2m. The trustees are considering measures to try and build up free reserves going forward and they will monitor the level of reserves as part of BTOG's financial processes.

If reserves were to exceed the agreed level (2 years' normal operating expenditure) BTOG will take immediate steps to reduce the level of those reserves either by increasing expenditure on charitable activities or by reducing its income (or a combination of both). The time frame for this reduction will be within 2 years of discovery of the excess and during that time the trustees will consider whether some or all the reserves can be invested to obtain a financial return for the charity.

STRUCTURE GOVERNANCE AND MANAGEMENT

Constitution

British Thoracic Oncology Group registered as a company (9816385) on 8th October 2015 and as a charity (1166012) on 11th March 2016. The company is limited by guarantee and has no share capital. Every member of the company undertakes to contribute to the assets of the company, in the event of winding up, such an amount as may be required not exceeding £1. The governing document is the Memorandum of Association.

Trustees

The following trustees have served since 1 April 2021:

Mr AM Grange (Chairman)
Mr C Kerr (Treasurer)
Professor MD Peake
Ms S Hiom
Professor D Talbot

Method of Appointment or Election of Trustees

The management of the charity is the responsibility of the trustees elected under the Memorandum of Association of BTOG. Trustees set the policies for the recruitment, induction and training of new trustees. In selecting individuals for appointment as new trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction pack which includes various items such as the governing document, the latest financial statements, policy documents and Charity Commission guidance.

Pay Policy for Staff

BTOG does not employ its own staff. An NHS Trust employs the staff and charges the associated salary costs to the charity in accordance with a service level agreement. Pay levels for posts supported by the charity are determined through standard NHS procedures.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making

The trustees are responsible for BTOG; they safeguard the values and purpose of BTOG and check activities contribute to achieving the objects and ensure BTOG follows its legal obligations. Trustees are Non-Executive Directors of BTOG. The current trustees comprise a Consultant and Honorary Professor of respiratory medicine who is also Clinical Co-Director of the Centre for Cancer Outcomes at UCLH, Honorary Clinical Lead for NHS Digital and a Specialist Clinical Advisor at Cancer Research UK; a former senior policy figure from Cancer Research UK of 20 years' standing who is now Director of Cancer Intelligence at GRAIL Europe; a retired professor/medical oncologist; a retired tax inspector and a retired senior pharmaceutical professional. The trustees and Steering Committee Chair decide the policies which provide the framework for the work of BTOG; decide overall aims and objectives, priorities and strategy; monitor and evaluate progress and delegate day-to-day work to the BTOG Senior Executive Officer and other appointed staff/agents. The trustees meet 4 times/year and communicate by email at all other times. One trustee also attends Steering Committee meetings as an observer (subject to availability).

The Steering Committee Chair is an Executive Officer of BTOG, accountable to the trustees. The Steering Committee supports BTOG's aims and objectives; take an active role in the delivery of the BTOG educational programme; comments and advises on thoracic oncology guidelines for care or treatment; represents BTOG on other thoracic oncology boards/committees/groups and recognises their affiliation to BTOG in their work. The Steering Committee are Executive Officers of BTOG, accountable to the SC Chair. The Steering Committee meet in person 4 times/year and communicate by email at all other times. The Steering Committee members represent the thoracic oncology multi-disciplinary team. In addition, BTOG recognises the importance of input from advocates in improving outcomes for lung cancer and mesothelioma patients and therefore the Steering Committee includes two advocate members. BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma.

BTOG is a member of the National Council for Voluntary Organisations (NCVO) and trustees have access to online resources and information for charities. The trustees are required to update their trustee knowledge and training regularly to ensure they understand their role and responsibilities. Trustees periodically attend both theoretical and practical training courses organised by the NCVO covering a wide variety of charitable issues and they also complete online training.

The Senior Executive Officer (SEO) carries out the work of BTOG; reports regularly on achievements and progress; makes decisions (where the power to do this has been delegated); provides information on issues, problems and policy matters and makes recommendations; draws up plans for the future development of BTOG's work for the Trustees and Steering Committee to decide upon; advises and informs the trustee board so that it is able to carry out its governing role and recruits and appoints staff/agents. The SEO is reportable to University Hospitals of Leicester NHS Trust (UHL) Line Manager and Steering Committee Chair and accountable to the trustees.

The relationship of the BTOG Executive is based on a shared vision for BTOG; a commitment to achieving the objectives of BTOG; clear and understood trustee roles to not interfere inappropriately with the day-to-day running of BTOG; confidence in the abilities of the SEO and willingness to back the judgement of the SEO in the event of problems (providing they have been kept informed); the provision of good information to enable informed decisions to be made and a clear management framework and lines of accountability.

The SEO and Executive Officer (EO) are paid roles employed by UHL, who charge the associated salary costs to the charity in accordance with a formal service level agreement. Communications/website, conference and accountancy services were contracted out to external commercial providers. All other roles in the BTOG Executive are unpaid.

For 15 years, BTOG was provided with office space by UHL and was based at Glenfield Hospital in Leicester. In August 2017, BTOG moved to external offices (within Mesothelioma UK) and from December 2018 to 30 September 2020, BTOG leased a dedicated office space adjacent to Mesothelioma UK. A formal Service Level Agreement was in place between BTOG and Mesothelioma UK (for use of IT equipment). With staff working from home during the pandemic, the charity made the decision to terminate the lease on 30 September 2020. Starting 1st February 2022, BTOG have leased an office from Mesothelioma UK in Mountsorrel, Leicester and there is a Memorandum of Understanding in place in this respect. BTOG staff do a combination of office and home working.

BTOG works collaboratively with many organisations including Mesothelioma UK (a related party) in the pursuit of its charitable activities.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making (continued)

BTOG recognised the need for appropriate governance to ensure transparent working and therefore has a comprehensive portfolio of policies covering charity structure, roles and responsibilities of trustees and the steering committee, conflict of interest, finance, procurement, reserves, endorsement, media and privacy, developed taking account of Charity Commission guidance. The policies are reviewed as per the review dates and new policies are developed as needed/identified and are available in the Governance section of the BTOG website.

The Trustees confirm that the major risks relating to BTOG have been reviewed and systems and procedures have been established to manage those risks, as detailed on page 26 under risk management.

Plans for future periods

The COVID-19 pandemic meant that BTOG adapted what we do to include a virtual CPD education programme, and this will be continued in the 2022/23 period and beyond. However, we plan to introduce in-person education again during 2022/23. BTOG will continue to work towards its strategic outcomes, mission and vision within the Strategic Plan 2020-2025 (on page 3). The next few years will be challenging as we all navigate further through the pandemic and hopefully continue through the recovery phase.

During the 2022/23 period and beyond we plan to:

- Continue to provide relevant CPD education (virtual and in-person). In-person will include an annual conference and essential updates;
- Provide networking, education and resources for trainees;
- Make www.btog.org the one-stop resource shop for trainees and all thoracic oncology health care professionals;
- Continue to provide "BTOG does ..." Podcasts;
- Develop BTOG's Research Strategy
- Identify other areas for the development of BTOG Special Interest Groups (SIG) complementing other external subgroups
- Begin work on developing a programme of Regional Updates including standard slide sets on relevant up-to-date research/data

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

Approved by the Board of Trustees on 22 August 2022 and signed on its behalf by:

Mr AM Grange
Chair of the Board of Trustees

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

I report to the trustees on my examination of the accounts of the company for the year ended 31 March 2022.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

P T Barnett FCCA (Independent Examiner)

Newby Castleman LLP
West Walk Building
110 Regent Road
Leicester
LE1 7LT

22 September 2022

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2022

	Notes	Unrestricted Funds Total 2022 £	Unrestricted Funds Total 2021 £
Income from:			
Charitable activities	3	58,736	-
Other trading activities	4	467,798	19,500
Total		526,534	19,500
Expenditure on:			
Raising funds	5	32,475	29,466
Charitable activities	6	254,155	111,300
Other	9	310	3,000
Total		286,940	143,766
Net income/(expenditure) for the year/ Net movement in funds		239,594	(124,266)
Reconciliation of funds			
Total funds brought forward		500,121	624,387
Total funds carried forward		739,715	500,121

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

BRITISH THORACIC ONCOLOGY GROUP

BALANCE SHEET

AS AT 31 MARCH 2022

		2022		2021	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	12		464		1,183
Current assets					
Debtors	13	195,210		141,882	
Cash at bank and in hand		671,482		591,233	
		<u>866,692</u>		<u>733,115</u>	
Liabilities					
Creditors: amounts falling due within one year	14	(127,441)		(234,177)	
Net current assets			739,251		498,938
Net assets			<u>739,715</u>		<u>500,121</u>
Total funds of the charity					
Designated funds		7,730		8,316	
General funds		<u>731,985</u>		<u>491,805</u>	
Total unrestricted funds	16		739,715		500,121
Total charity funds			<u>739,715</u>		<u>500,121</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2022.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

Trustees' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006;
- The trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of the accounts.

The financial statements were approved and authorised for issue by the Board of Trustees on 22 August 2022 and are signed on its behalf by:

Mr C Kerr
Trustee and Treasurer

Company Registration No. 9816385

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 MARCH 2022

	Notes	2022 £	£	2021 £	£
Cash flows from operating activities					
Cash generated from operations	21		80,249		220,479
Investing activities					
Purchase of tangible fixed assets		-		(592)	
Net cash used in investing activities			-		(592)
Net cash used in financing activities			-		-
Net increase in cash and cash equivalents			80,249		219,887
Cash and cash equivalents at beginning of year			591,233		371,346
Cash and cash equivalents at end of year			671,482		591,233

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

Charity information

British Thoracic Oncology Group ("BTOG") is a private company limited by guarantee incorporated in England and Wales. The address of the registered office and place of business is given in the legal and administrative information page of these financial statements.

The members of the charity include the trustees named within the legal and administrative information. In the event of the trust being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

1.1 Basis of preparation

The charity is a Public Benefit Entity as defined by FRS 102. The financial statements have been prepared in accordance with: the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Designated funds are unrestricted funds of the charity which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Income from charitable activities primarily includes income received for conference and course registration fees. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, if it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Income from trading activities includes income earned from sponsorship.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

(Continued)

1.5 Expenditure recognition

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is legal or constructive obligation to make the payment to a third party, if it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Expenditure on raising funds - this includes costs for advertising, marketing, direct mail and publicity.
- Expenditure on charitable activities - this includes services to further the delivery of the objectives of the charity.

Irrecoverable VAT is charged against the category of resources expensed for which it was incurred.

Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs and governance costs. They are incurred directly in support of expenditure on the objects of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 9.

1.6 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Fixtures & fittings	15% of cost
Computer equipment	33.33% of cost

1.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.8 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the SOFA.

1.9 Taxation

British Thoracic Oncology Group is a registered charity and no taxation provision is required as its income from charitable activities falls within the various exemptions available to registered charities.

1.10 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies (Continued)

1.11 Leases

Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements.

3 Charitable activities

	Unrestricted funds £	Restricted funds £	Total 2022 £	Total 2021 £
Conference and course registration fees	58,736	-	58,736	-
Unrestricted funds				-
Restricted funds				-
				-

4 Other trading activities

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Total 2021 £
Sponsorship	467,798	-	467,798	19,500
Unrestricted funds				19,500
Restricted funds				-
				19,500

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

5 Raising funds

	Unrestricted funds £	Restricted funds £	Total 2022 £	Total 2021 £
Advertising, marketing, direct mail and publicity	14,363	-	14,363	12,513
Support costs (see note 8)	18,112	-	18,112	16,953
	<u>32,475</u>	<u>-</u>	<u>32,475</u>	<u>29,466</u>
Unrestricted funds				29,466
Restricted funds				-
				<u>29,466</u>

6 Charitable activities

	Activities undertaken directly Note 7 £	Support Costs Note 8 £	Total 2022 £	Total 2021 £
Conference and courses	169,912	84,243	254,155	111,300
Unrestricted funds			254,155	111,300
Restricted funds			-	-
			<u>254,155</u>	<u>111,300</u>

7 Expenditure on activities undertaken directly

	2022 £	2021 £
Conference and courses		
Venue and accommodation management	29,499	-
Abstract publication	26,630	-
Prizes and bursaries	3,300	-
Course accreditation	695	360
Bank and card charges	1,714	-
Webinar activities	108,074	23,028
	<u>169,912</u>	<u>23,388</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

8 Expenditure on support costs

	Basis of allocation	2022 £	2021 £
Staff costs	Raising funds and charitable activities	90,562	84,764
Travel	Charitable activities	665	725
Training	Charitable activities	-	753
Subscriptions	Charitable activities	486	402
Rent	Charitable activities	650	1,500
Insurance	Charitable activities	1,677	1,950
Office costs	Charitable activities	1,318	2,294
Software costs	Charitable activities	1,291	1,049
Bad debts	Charitable activities	-	2,910
Governance	Charitable activities	5,120	7,663
Sundry	Charitable activities	177	102
Depreciation	Charitable activities	409	753
		<u>102,355</u>	<u>104,865</u>
Analysed between:			
Raising funds		18,112	16,953
Charitable activities		84,243	87,912
		<u>102,355</u>	<u>104,865</u>

Support costs have been allocated to raising funds and charitable activities on a basis consistent with the use of the resource. Support costs include governance costs totalling £5,120 (2021: £7,663).

The amount charged to the SOFA in respect of governance costs includes the following:

Independent examination £4,000 (2021 - £3,850)

VAT advisory services £nil (2021 - £1,400)

Other financial services £1,120 (2021 - £2,413)

9 Other expenditure

	Unrestricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Total 2021 £
Net loss on disposal of tangible fixed assets	310	310	-	-
Interest	-	-	3,000	3,000
	<u>310</u>	<u>310</u>	<u>3,000</u>	<u>3,000</u>

The company classifies certain one-off charges and credits which have a material impact on the company's financial results as 'exceptional items'. These are disclosed separately to provide further understanding of the financial performance of the company.

Interest in the sum of £3,000 relates to late payment of the total VAT liability of £50,005 in respect of the four years ended 31 March 2020, following a review of the charity's VAT affairs.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

10 Trustees

The trustees neither received nor waived any emoluments during the year (2020: £Nil).

No travel and subsistence expenses were reimbursed to trustees during the year or preceding year.

11 Employees

Number of employees

The average monthly number of employees during the year was:

	2022 Number	2021 Number
Total	2	2

Employment costs

	2022 £	2021 £
Wages and salaries	90,562	84,764

Staff working for the charity are employed directly by the University Hospitals of Leicester NHS Trust and their salary costs are charged to the charity in accordance with a service level agreement between BTOG and the Trust. The amount charged for the year was £90,562 (2021 - £87,764).

There were no employees whose annual remuneration was £60,000 or more.

12 Tangible fixed assets

	Fixtures & fittings £	Computer equipment £	Total £
Cost			
At 1 April 2021	1,257	1,689	2,946
Disposals	(565)	-	(565)
At 31 March 2022	692	1,689	2,381
Depreciation and impairment			
At 1 April 2021	489	1,274	1,763
Depreciation charged in the year	105	304	409
Eliminated in respect of disposals	(255)	-	(255)
At 31 March 2022	339	1,578	1,917
Carrying amount			
At 31 March 2022	353	111	464
At 31 March 2021	768	415	1,183

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

13 Debtors

	2022 £	2021 £
Amounts falling due within one year:		
Trade debtors	155,590	115,712
Other debtors	7,730	8,316
Prepayments and accrued income	31,890	17,854
	<u>195,210</u>	<u>141,882</u>

14 Creditors: amounts falling due within one year

	2022 £	2021 £
Other taxation and social security	43,565	35,002
Deferred income (see note 16)	74,866	190,000
Accruals	9,010	9,175
	<u>127,441</u>	<u>234,177</u>

15 Deferred income

	2022 £	2021 £
Arising from advanced registration fees and sponsorships	<u>74,866</u>	<u>190,000</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

16 Unrestricted funds

The unrestricted funds of the charity include designated funds which have been set aside out of unrestricted funds by the trustees for a specific purpose:

	Balance at 1 April 2021 £	Income £	Movement in funds Expenditure £	Transfers £	Prior period Adjustment £	Balance at 31 March 2022 £
General funds	491,805	526,534	(196,354)	(90,000)	-	731,985
Designated funds - wages fund	8,316	-	(90,586)	90,000	-	7,730
	<u>500,121</u>	<u>526,534</u>	<u>(286,940)</u>	<u>-</u>	<u>-</u>	<u>739,715</u>

	Balance at 1 April 2020 £	Income £	Movement in funds Expenditure £	Transfers £	Prior period Adjustment £	Balance at 31 March 2021 £
General funds	591,758	19,500	(28,639)	(60,500)	(30,314)	491,805
Designated funds - wages fund	32,629	-	(84,813)	60,500	-	8,316
	<u>624,387</u>	<u>19,500</u>	<u>(113,452)</u>	<u>-</u>	<u>(30,314)</u>	<u>500,121</u>

The wages fund represents funds held by the University Hospitals of Leicester NHS Trust as Custodian Trustee on behalf of British Thoracic Oncology Group for primarily the payment of wages to staff working for the charity but who are employed by the NHS Trust.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

17 Analysis of net assets between funds

	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2022 are represented by:			
Tangible assets	464	-	464
Current assets/(liabilities)	731,521	7,730	739,251
	<u>731,985</u>	<u>7,730</u>	<u>739,715</u>
	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2021 are represented by:			
Tangible assets	1,183	-	1,183
Current assets/(liabilities)	490,622	8,316	498,938
	<u>491,805</u>	<u>8,316</u>	<u>500,121</u>

18 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2022 £	2021 £
Aggregate compensation	<u>57,356</u>	<u>54,050</u>

During the year rent and office expenses in the sum of £1,478 (2021 - £1,968) were invoiced by Mesothelioma UK Charitable Incorporated Organisation (formerly Mesothelioma UK Charitable Trust) to the British Thoracic Oncology Group. Professor M D Peake and Ms D E McKinley are both trustees of these organisations. At the balance sheet date there was an outstanding balance of £nil (2021 - £nil) for these services.

No travel expenses were due to be reimbursed to any trustees at the year end or last year end.

Travel and subsistence expenses were reimbursed to 1 member (2021: 0) of key management personnel in the sum of £327 (2021: £nil) during the year.

There have been no further related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 11 to the financial statements.

19 Controlling party

British Thoracic Oncology Group is a company limited by guarantee and not having a share capital; it is incorporated under the Companies Act and governed by the Memorandum and Articles of Association of the charity. The trustees of the charity are elected members and act as directors of the charity who are deemed to be the controlling party of the charity.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

20 Operating lease commitments

At 31 March 2022 the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2022 £	2021 £
Within one year	3,250	-

Lease payments totalling £650 (2021 - £1,500) have been recognised as an expense during the year.

21 Cash generated from operations

	2022 £	2021 £
Surplus/(deficit) for the year	239,594	(124,266)
Adjustments for:		
Loss on disposal of tangible fixed assets	310	-
Depreciation and impairment of tangible fixed assets	409	753
Movements in working capital:		
(Increase)/decrease in debtors	(53,328)	191,022
Increase/(decrease) in creditors	8,398	(29,530)
(Decrease)/increase in deferred income	(115,134)	182,500
Cash generated from operations	80,249	220,479